1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca Looks To Many Modalities In Cancer

US Oncology Head Talks Strategy With Scrip

 
• By Jessica Merrill

Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.

Mohit Manrao, VP, Global Franchise Head Lung Cancer, Oncology Business Unit, AstraZeneca
AstraZeneca US head of oncology Mohit Manrao • Source: AstraZeneca

AstraZeneca PLC has an ambitious goal to move from the number four cancer drug company in the world toward the top ranking and is relying on a diverse pipeline to continue the company’s impressive growth trajectory in oncology.

Senior VP and head of the US oncology business unit Mohit Manrao talked to Scrip about the company’s US oncology growth outlook, the diverse pipeline that spans a wide array of modalities, and recent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas